http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108309982-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_53b4d53983adbf56dd0e7d0bf96f8ce5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2017-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6701de291c44c4953db0394e397650d3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e0eb28dc6ebcc88858112aa0a8675d0 |
| publicationDate | 2018-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108309982-A |
| titleOfInvention | Use of 3-substituted 5H-[1,2,4]triazine[5,6-b]indole derivatives |
| abstract | The invention belongs to the field of biomedicine, and specifically relates to the use of 3-substituted 5H-[1,2,4]triazine[5,6-b]indole derivatives. The invention provides the use of 3-substituted 5H-[1,2,4]triazine[5,6-b]indole derivatives, specifically 3-substituted 5H-[1,2,4]triazine [5,6-b] Use of indole derivatives and salts or hydrates thereof, or pharmaceutical compositions containing them in the preparation of SIRT2 inhibitors, drugs for treating or preventing cancer, and drugs for treating or preventing neurodegenerative diseases. The structure of the 3-substituted 5H-[1,2,4]triazine[5,6-b]indole derivative is shown in formula I. The 3-position substituted 5H-[1,2,4]triazine[5,6-b]indole derivative compound of the present invention and the pharmaceutical composition of its salt or hydrate are used in the treatment or prevention of cancer, treatment or prevention It has a role in neurodegenerative diseases, and provides a new option for the development of SIRT2 inhibitors, anti-tumor and anti-psychotic diseases in this field, and has a good application prospect. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112939955-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113354651-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2022511496-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113801075-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113354651-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7224463-B2 |
| priorityDate | 2017-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.